1 citations
,
November 2021 in “Société internationale d'urologie journal” Doctors should adjust how they treat men with prostate-related urinary problems during and after the COVID-19 pandemic.
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
Evidence-based urology improved treatment and quality of life for conditions like BPH by shifting from surgery to effective medications like finasteride and dutasteride.
April 2014 in “The FASEB Journal” Testosterone reduces knee movement, while flutamide and finasteride increase it.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
47 citations
,
January 2003 in “Current opinion in urology” A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
2 citations
,
March 2020 in “Baghdad Science Journal” Finasteride effectively reduces DHT and E2 levels, helping with prostate enlargement.
4 citations
,
August 2011 in “The Lancet Oncology” Off-label drug use can be risky and requires careful consideration to ensure patient safety.
17 citations
,
February 2001 in “Urologia Internationalis” Stopping alpha-blocker medication after 6-9 months is safe and effective for most patients with bladder outlet obstruction.
2 citations
,
January 2023 in “Uro” UHP-sCESr is as effective as HESr for treating BPH symptoms.
September 2014 in “PubMed Central” BPH treatments can cause sexual side effects affecting quality of life.
62 citations
,
January 2004 in “PubMed” 5alpha-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT, offering symptom relief and potential future uses.
4 citations
,
March 2018 in “Journal of labelled compounds & radiopharmaceuticals” A new compound was effective for imaging prostate cancer in rats.
1 citations
,
October 2024 in “JCEM Case Reports” 5α-reductase deficiency can cause ambiguous genitalia and gender dysphoria, treatable with testosterone.
December 2013 in “Urology reports (St - Petersburg)” Sonirid Duo effectively treats benign prostatic hyperplasia.
October 2006 in “The Lancet Oncology” Finasteride reduces prostate cancer risk but may increase aggressive cancer risk slightly.
August 2013 in “Nature Reviews Drug Discovery” New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.
1 citations
,
November 2023 in “American journal of clinical pathology” Transgender men on testosterone therapy need ongoing gynecologic care due to potential cancer risks.
January 2012 in “International Journal of Trichology” Two siblings have a rare genetic condition causing curly, coarse hair.
March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.
December 2024 in “Journal of Cancer Therapy and Research” Artocarpus heterophyllus seed extract may help treat prostate inflammation without side effects.
1 citations
,
December 2013 in “Urological Science” A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.
20 citations
,
May 2018 in “The Journal of Urology” Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.
March 2026 in “Gazzetta Medica Italiana Archivio per le Scienze Mediche” Finasteride effectively treats benign prostatic hyperplasia by reducing prostate size and improving urinary symptoms.
May 2016 in “Endocrine Abstracts” The removal of the adrenal tumor improved the patient's symptoms and reduced androgen levels, indicating successful surgery.
4 citations
,
October 2018 in “International Braz J Urol” Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.
February 2004 in “European Urology Supplements” 4 citations
,
January 2002 Alpha-blockers and Finasteride effectively manage BPH symptoms long-term.
2 citations
,
February 2006 in “Mayo Clinic Proceedings” Finasteride is beneficial for BPH but requires careful monitoring due to cancer risks.
21 citations
,
October 2015 in “Current Drug Targets” Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.